Nucleostemin Depletion Induces Post-g1 Arrest Apoptosis in Chronic Myelogenous Leukemia K562 Cells

Overview

Journal Adv Pharm Bull

Date 2014 Jan 11

PMID 24409410

Citations 7

Authors

Negin Seyed-Gogani

Marveh Rahmati

Nosratollah Zarghami

Iraj Asvadi-Kermani

Mohammad Ali Hoseinpour-Feyzi

Mohammad Amin Moosavi

Affiliations

Soon will be listed here.

Abstract

Purpose: Despite significant improvements in treatment of chronic myelogenous leukemia (CML), the emergence of leukemic stem cell (LSC) concept questioned efficacy of current therapeutical protocols. Remaining issue on CML includes finding and targeting of the key genes responsible for self-renewal and proliferation of LSCs. Nucleostemin (NS) is a new protein localized in the nucleolus of most stem cells and tumor cells which regulates their self-renewal and cell cycle progression. The aim of this study was to investigate effects of NS knocking down in K562 cell line as an in vitro model of CML.

Methods: NS gene silencing was performed using a specific small interfering RNA (NS-siRNA). The gene expression level of NS was evaluated by RT-PCR. The viability and growth rate of K562 cells were determined by trypan blue exclusion test. Cell cycle distribution of the cells was analyzed by flow cytometry.

Results: Our results showed that NS knocking down inhibited proliferation and viability of K562 cells in a time-dependent manner. Cell cycle studies revealed that NS depletion resulted in G(1) cell cycle arrest at short times of transfection (24 h) followed with apoptosis at longer times (48 and 72 h), suggest that post-G1 arrest apoptosis is occurred in K562 cells.

Conclusion: Overall, these results point to essential role of NS in K562 cells, thus, this gene might be considered as a promising target for treatment of CML.

Citing Articles

Proteomic Investigation of the Role of Nucleostemin in Nucleophosmin-Mutated OCI-AML 3 Cell Line.

Cela I, Cufaro M, Fucito M, Pieragostino D, Lanuti P, Sallese M Int J Mol Sci. 2022; 23(14).

PMID: 35886999 PMC: 9317519. DOI: 10.3390/ijms23147655.

Association of Nucleostemin Polymorphisms with Chronic Hepatitis B Virus Infection in Chinese Han Population.

Li J, Xu J, Wang Y, Li Q, Sun X, Fu W Genet Test Mol Biomarkers. 2022; 26(5):255-262.

PMID: 35638911 PMC: 9150128. DOI: 10.1089/gtmb.2021.0181.

Silencing of Nucleostemin by siRNA Induces Apoptosis in MCF-7 and MDA-MB-468 Cell Lines.

Moudi M, Saravani R, Sargazi S Iran J Pharm Res. 2020; 19(1):37-45.

PMID: 32922467 PMC: 7462512. DOI: 10.22037/ijpr.2020.1100950.

Cytokines secreted from bone marrow derived mesenchymal stem cells promote apoptosis and change cell cycle distribution of K562 cell line as clinical agent in cell transplantation.

Fathi E, Farahzadi R, Valipour B, Sanaat Z PLoS One. 2019; 14(4):e0215678.

PMID: 31009502 PMC: 6476492. DOI: 10.1371/journal.pone.0215678.

Differential expression of nucleostemin in the cytoplasm and nuclei of normal and cancerous cell lines.

Kavyasudha C, Joel J, Devi A Turk J Biol. 2019; 42(3):250-258.

PMID: 30814887 PMC: 6353292. DOI: 10.3906/biy-1712-10.

References

Moosavi M, Yazdanparast R . Distinct MAPK signaling pathways, p21 up-regulation and caspase-mediated p21 cleavage establishes the fate of U937 cells exposed to 3-hydrogenkwadaphnin: differentiation versus apoptosis. Toxicol Appl Pharmacol. 2008; 230(1):86-96. DOI: 10.1016/j.taap.2008.02.010. View

Lubbert M, Miller C, Crawford L, Koeffler H . p53 in chronic myelogenous leukemia. Study of mechanisms of differential expression. J Exp Med. 1988; 167(3):873-86. PMC: 2188905. DOI: 10.1084/jem.167.3.873. View

Liu S, Cai Z, Liu Y, Dong M, Sun L, Hu G . Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. World J Gastroenterol. 2004; 10(9):1246-9. PMC: 4622760. DOI: 10.3748/wjg.v10.i9.1246. View

Nikpour P, Mowla S, Jafarnejad S, Fischer U, Schulz W . Differential effects of Nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710. Cell Prolif. 2009; 42(6):762-9. PMC: 6495913. DOI: 10.1111/j.1365-2184.2009.00635.x. View

Jafarnejad S, Mowla S, Matin M . Knocking-down the expression of nucleostemin significantly decreases rate of proliferation of rat bone marrow stromal stem cells in an apparently p53-independent manner. Cell Prolif. 2008; 41(1):28-35. PMC: 6496312. DOI: 10.1111/j.1365-2184.2007.00505.x. View

Ma H, Pederson T . Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell. 2007; 18(7):2630-5. PMC: 1924810. DOI: 10.1091/mbc.e07-03-0244. View

Sell S . Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2006; 1(3):197-205. DOI: 10.1385/SCR:1:3:197. View

Tefferi A, Dewald G, Litzow M, Cortes J, Mauro M, Talpaz M . Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment. Mayo Clin Proc. 2005; 80(3):390-402. DOI: 10.4065/80.3.390. View

Thiesing J, Kolibaba K, Druker B . Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000; 96(9):3195-9. View

10.

Nomura J, Maruyama M, Katano M, Kato H, Zhang J, Masui S . Differential requirement for nucleostemin in embryonic stem cell and neural stem cell viability. Stem Cells. 2009; 27(5):1066-76. DOI: 10.1002/stem.44. View

11.

Moosavi M, Yazdanparast R, Lotfi A . ERK1/2 inactivation and p38 MAPK-dependent caspase activation during guanosine 5'-triphosphate-mediated terminal erythroid differentiation of K562 cells. Int J Biochem Cell Biol. 2007; 39(9):1685-97. DOI: 10.1016/j.biocel.2007.04.016. View

12.

Sijin L, Ziwei C, Yajun L, Meiyu D, Hongwei Z, Guofa H . The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells. J Exp Clin Cancer Res. 2004; 23(3):529-38. View

13.

Liu R, Zhang Z, Zhao W, Wang M, Qi S, Li J . Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells. Chin Med J (Engl). 2008; 121(4):299-304. View

14.

Deininger M, Goldman J, Melo J . The molecular biology of chronic myeloid leukemia. Blood. 2000; 96(10):3343-56. View

15.

Normile D . Cell proliferation. Common control for cancer, stem cells. Science. 2002; 298(5600):1869. DOI: 10.1126/science.298.5600.1869. View

16.

Ma H, Pederson T . Nucleostemin: a multiplex regulator of cell-cycle progression. Trends Cell Biol. 2008; 18(12):575-9. DOI: 10.1016/j.tcb.2008.09.003. View

17.

Druker B, Sawyers C, Kantarjian H, Resta D, Reese S, Ford J . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344(14):1038-42. DOI: 10.1056/NEJM200104053441402. View

18.

Kafienah W, Mistry S, Williams C, Hollander A . Nucleostemin is a marker of proliferating stromal stem cells in adult human bone marrow. Stem Cells. 2005; 24(4):1113-20. DOI: 10.1634/stemcells.2005-0416. View

19.

Tsai R, McKay R . A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev. 2002; 16(23):2991-3003. PMC: 187487. DOI: 10.1101/gad.55671. View

20.

Wong S, Witte O . The BCR-ABL story: bench to bedside and back. Annu Rev Immunol. 2004; 22:247-306. DOI: 10.1146/annurev.immunol.22.012703.104753. View